BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
17 oct. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
15 oct. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
02 oct. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting
30 sept. 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting
BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
29 août 2024 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers
21 août 2024 07h00 HE
|
Biostem Technologies
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje®
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
12 août 2024 16h14 HE
|
Biostem Technologies
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million
BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
05 août 2024 08h00 HE
|
Biostem Technologies
BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
10 juil. 2024 07h15 HE
|
Biostem Technologies
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
26 juin 2024 08h30 HE
|
Biostem Technologies
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study